Alembic Pharmaceuticals Secures FDA Approval for Generic Zylet Ophthalmic Suspension with CGT Exclusivity
核心洞察
Alembic Pharmaceuticals received final FDA approval for its generic version of Zylet ophthalmic suspension containing loteprednol etabonate and tobramycin for treating inflammatory eye conditions with bacterial infection risk.
The company was granted Competitive Generic Therapy designation, making it eligible for 180 days of market exclusivity upon commercialization of the product.
This approval brings Alembic's total ANDA approvals from the US FDA to 231, comprising 211 final approvals and 20 tentative approvals.
Alembic Pharmaceuticals announced it has received final approval from the US Food & Drug Administration (搜索) for its Abbreviated New Drug Application for Loteprednol Etabonate and Tobramycin Ophthalmic Suspension, 0.5%/0.3%, available in 5 mL and 10 mL presentations. The approval represents a significant milestone for the Indian pharmaceutical company's US generics portfolio.
Therapeutic Equivalence and Market Position
The approved ANDA is listed as therapeutically equivalent to the reference listed drug Zylet Ophthalmic Suspension, 0.5%/0.3%, marketed by Bausch & Lomb Incorporated. This therapeutic equivalence designation confirms that Alembic's generic formulation meets the same standards of safety and efficacy as the brand-name product.
The ophthalmic suspension is indicated for steroid-responsive inflammatory ocular conditions (搜索) for which a corticosteroid is indicated and where superficial bacterial ocular infection (搜索) or a risk of bacterial ocular infection exists. The dual-action formulation combines the anti-inflammatory properties of loteprednol etabonate with the antibiotic effects of tobramycin.
Competitive Generic Therapy Designation
Alembic received a Competitive Generic Therapy designation for the application, a significant regulatory advantage that provides market exclusivity benefits. With this approval, the company is eligible for 180 days of CGT exclusivity upon commercialization following this approval. This exclusivity period can provide substantial competitive advantages in the generic pharmaceutical market.
Expanding ANDA Portfolio
This latest approval adds to Alembic's growing presence in the US pharmaceutical market. The company now has a cumulative total of 231 ANDA approvals from the USFDA, comprising 211 final approvals and 20 tentative approvals. This milestone reflects the company's consistent regulatory success and expanding generic drug portfolio.
Alembic Pharmaceuticals Limited is described as a vertically integrated research and development pharmaceutical company that has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products globally.